Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has reported E.P.S. of $0.02 for its third fiscal quarter (ending September 30) versus $0.10 for the same period a year ago — a decline of -80%. E.P.S. were $-0.02 for the latest four quarters through September 30 versus $-6.13 for the same period a year ago — a decline of -100%.
Recent Price Action
On 11/7/24, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) stock suffered a large decline of -7.5%, closing at $4.66. Moreover, this decline was accompanied by above average trading volume at 129% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 12.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, IRWD is expected to be a major Value Eraser.
Ironwood Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment